Remove Bioinformatics Remove Drug Development Remove Treatment Remove Workshop
article thumbnail

Looking ahead to AACR  

Drug Discovery World

Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics, to global health, survivorship, prevention and tumour biology, to name just a few. Science ↔ Survivor Program As mentioned previously, AACR has a Scientist↔Survivor Program.

article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

These different fundamental approaches (rules-based versus pattern recognition) to building these systems provide multiple opportunities to interject them into disease diagnostics and treatments. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Science 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You Leaders at FDA share highlights and updates for drugs and biologics at RAPS Convergence

Agency IQ

Joneckis said that CBER has “some limited uses that we have seen in external submissions, mostly in the bioinformatics area,” but not as many as CDER. Regarding artificial intelligence (AI), an important topic at RAPS Convergence, the two centers discussed external and internal use cases.

FDA 40
article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

Synthetic libraries for antibody drug discovery . Developing therapeutic antibodies, one of the most successful approaches in drug development, involves identifying and characterising antibodies to be used as treatment against different types of cancers as well as autoimmune and cardiovascular diseases.

DNA 246